pipeline-prospector-insert-v1
X

Find Novel Neurology Drugs in Preclinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SLS-007

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            Seelos is to begin an in-vivo study delivering SLS-007 by an Adeno-Associated Virus (AAV) vector making the program Seelos’ second gene therapy approach for Parkinson’s Disease (PD).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Apilimod mesylate,Rituximab,Atezolizumab

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 16, 2020

            Details:

            Company receives FDA guidance for pivotal trial design in follicular lymphoma to support accelerated and full approval.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BIO-205

            Therapeutic Area: Neurology

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: MPM Capital

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 07, 2020

            Details:

            The financing will be used to advance the company’s lead program, BIO-205, through human proof-of-concept studies in neuropathic pain as well as to advance its portfolio of A3AR agonists.